PDS Implant Pre-Filled with 100 mg/mL Ranibizumab
Sponsors
Hoffmann-La Roche
Conditions
Diabetic Macular EdemaDiabetic Retinopathy
Phase 3
A Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Substudy to Evaluate the Safety of Re-implanting the PDS With Ranibizumab in Participants With DME
Active, not recruitingNCT04108156
Start: 2019-09-30End: 2027-07-20Updated: 2026-07-10
A Multicenter, Randomized Study in Participants With Diabetic Retinopathy Without Center-involved Diabetic Macular Edema To Evaluate the Efficacy, Safety, and Pharmacokinetics of Ranibizumab Delivered Via the Port Delivery System Relative to the Comparator Arm
CompletedNCT04503551
Start: 2020-08-10End: 2026-02-23Updated: 2026-04-02